Phibro Animal Health and Zydus Cadila recently announced their intention to enter into a long-term deal that would see the Indian company license Israeli Phibro’s innovative poultry vaccine technologies.

A Globes report said the five-year deal was worth $150 million.

“We are proud of the more than 20-year partnership with Zydus Cadila serving the Indian animal health market and we view this as an exciting next step in our relationship,” said Jack Bendheim, Chairman, President and Chief Executive Officer of Phibro.

Phibro is a developer, manufacturer and marketer of animal health and mineral nutrition products for use in the production of poultry, swine, dairy, beef cattle and aquaculture.

“Our endeavor has always been to enable access to innovative therapies across geographies and this agreement with Phibro will help bring innovations to the poultry market in India. The availability of new advanced poultry vaccines, which were until now being imported into India, adds a new dimension to the Make-in-India movement in the animal health segment,” said Pankaj R. Patel, Chairman and Managing Director, Zydus.